Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dmLT vaccine for ETEC in healthy adults
NCT03548064Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Liposomes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of dmLT in enterotoxigenic Escherichia coli infection (9 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants in the Oral Arms With Solicited Local Reactogenicity Events Post Each Dose, Number of Participants in the Sublingual Arms With Solicited Local Reactogenicity Events Post Each Dose and 6 more. Started Mar 2019; status: terminated.
02
Drugs
dmLT
03
Conditions
enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT03548064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548064.